LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Two Simple Serum Biomarkers Differentiate Lymphoma from Glioma

By LabMedica International staff writers
Posted on 22 Apr 2022
Print article
Image: Micrograph of brain tissue with glioma enlargement and disease histology (Photo courtesy of 123rf.com)
Image: Micrograph of brain tissue with glioma enlargement and disease histology (Photo courtesy of 123rf.com)

A recent study found that two simple serum biomarkers, absolute lymphocyte count and prognostic nutritional index, which are easily derived from routine pre-treatment blood tests, have fair correlation and acceptable diagnostic accuracy for differentiating primary central nervous system lymphoma (PCNSL) from high-grade glioma (HGG) in patients with similar morphology on MRI.

A complex series of interactions take place between cancer and inflammation that are reflected by increased release of inflammatory biomarkers into the bloodstream. However, the utility of systemic inflammatory biomarkers as a means for the noninvasive differential diagnosis of PCNSL from HCC is generally lacking.

To repair this lack, investigators at the Homi Bhabha National Institute (Mumbai, India) and their colleagues carried out a study that involved calculating systemic inflammatory indices from pre-treatment complete blood counts and liver function tests and comparing them against histopathology as the reference standard among 42 patients with PCNSL and 16 with HGG.

Results revealed that the area under the receiver operating characteristics curve for absolute lymphocyte count and prognostic nutritional index in the diagnosis of PCNSL was 0.70 and 0.72 respectively, which suggested that these markers yielded fair and acceptable diagnostic accuracy.

The investigators said, "This exploratory first-of-a kind study assessed the utility of systemic inflammatory biomarkers derived from routine blood investigations in a cohort of patients with suspected PCNSL to differentiate them reliably from HGG with similar morphologic imaging."

The study was published in the April 4, 2022, online edition of the journal CNS Oncology.

Related Links:
Homi Bhabha National Institute 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more